This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Drug Therapy  • Drug Therapy, Other  • Gastroenterology  • Gastrointestinal Diseases  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Time to Consider Making the Switch?

Nimish Vakil, MD; Dino Vaira, MD

JAMA. 2008;300(11):1346-1347.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Helicobacter pylori infection remains an important cause of morbidity and mortality worldwide. Attempts at developing a vaccine have failed, and the current focus for clinicians is the treatment of the infection. Eradication of H pylori has been shown to prevent recurrent peptic ulcer disease, to cure some localized gastric mucosa–associated lymphoid tissue lymphomas, and to prevent nonsteroidal anti-inflammatory drug (NSAID)–related ulcers in patients who are initiating long-term NSAID therapy.¹ In recent years, the rate of treatment failure associated with established drug regimens has increased at a rapid rate.²

Antibiotic Delivery and Antimicrobial Resistance

Helicobacter pylori is uniquely adapted to life in the stomach. Its location in the gastric mucus, where it does not invade the gastric epithelium, provides the organism with protection from the host immune mechanisms and results in several challenges for delivery of antimicrobial agents to eradicate H pylori infection. For example, clarithromycin, a key component of . . . [Full Text of this Article]

Author Affiliations: University of Wisconsin School of Medicine and Public Health, Madison (Dr Vakil); and University of Bologna, Bologna, Italy (Dr Vaira).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?